Endocrine treatment of transsexual people: A review of treatment regimens, outcomes, and adverse effects

被引:213
作者
Moore, E
Wisniewski, A
Dobs, A
机构
[1] Johns Hopkins Univ Hosp, Div Endocrinol & Metab, Sch Med, Dept Med, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ Hosp, Dept Pediat, Sch Med, Baltimore, MD 21287 USA
关键词
D O I
10.1210/jc.2002-021967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cross-sex hormone treatment is an important component in medical treatment of transsexual people. Endocrinologists are often faced with designing treatment recommendations. Although guidelines from organizations, such as the Harry Benjamin International Gender Dysphoria Association, have been helpful, management remains complex and experience guided. We discuss the range of treatment used by transsexual people, the rationale behind these, and the expectation from such treatment. Recommendations from seven clinical research centers treating transsexual people are discussed. In addition, self-reported hormonal regimens from 25 male-to-female transsexual people and five female-to-male transsexual people are reported. Finally, the potential adverse effects of cross-sex hormone treatment of transsexual people are reviewed. In light of the complexity of managing treatment goals and adverse effects, the active involvement of a medical doctor experienced in cross-sex hormonal therapy is vital to ensure the safety of transsexual people.
引用
收藏
页码:3467 / 3473
页数:7
相关论文
共 59 条
[1]   SOME ASPECTS OF INTERACTION BETWEEN NATURAL AND SYNTHETIC FEMALE SEX HORMONES AND LIVER [J].
ADLERCREUTZ, H ;
TENHUNEN, R .
AMERICAN JOURNAL OF MEDICINE, 1970, 49 (05) :630-+
[2]   FOCAL NODULAR HYPERPLASIA OF LIVER ASSOCIATED WITH HIGH-DOSAGE ESTROGENS [J].
ALDINGER, K ;
BENMENACHEM, Y ;
WHALEN, G .
ARCHIVES OF INTERNAL MEDICINE, 1977, 137 (03) :357-359
[3]  
Ammus S S, 1989, Adv Intern Med, V34, P191
[4]  
[Anonymous], 1992, Journal of Psychology Human Sexuality, DOI DOI 10.1300/J056V05N04_03
[5]  
ASSCHEMAN H, 1988, CLIN ENDOCRINOL, V28, P583, DOI 10.1111/j.1365-2265.1988.tb03849.x
[6]   MORTALITY AND MORBIDITY IN TRANSSEXUAL PATIENTS WITH CROSS-GENDER HORMONE-TREATMENT [J].
ASSCHEMAN, H ;
GOOREN, LJG ;
EKLUND, PLE .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1989, 38 (09) :869-873
[7]   THE PREVALENCE OF TRANSSEXUALISM IN THE NETHERLANDS [J].
BAKKER, A ;
VANKESTEREN, PJM ;
GOOREN, LJG ;
BEZEMER, PD .
ACTA PSYCHIATRICA SCANDINAVICA, 1993, 87 (04) :237-238
[8]   POLYCYSTIC OVARIES ARE A COMMON FINDING IN UNTREATED FEMALE TO MALE-TRANSSEXUALS [J].
BALEN, AH ;
SCHACHTER, ME ;
MONTGOMERY, D ;
REID, RW ;
JACOBS, HS .
CLINICAL ENDOCRINOLOGY, 1993, 38 (03) :325-329
[9]   ANDROGENS - RISKS AND BENEFITS [J].
BARDIN, CW ;
SWERDLOFF, RS ;
SANTEN, RJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (01) :4-7
[10]   Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent [J].
Cohen-Kettenis, PT ;
van Goozen, SHM .
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 1998, 7 (04) :246-248